NCT00374933View on ClinicalTrials.gov

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI

"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"

DRUG

"Prophylactic delayed ADLI"

"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"

DRUG

"Prophylactic delayed activated donor lymphocyte infusion"

"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00374933 - Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | Biotech Hunter | Biotech Hunter